Adva Biotechnology and Autolomous Launch Digital Pioneer Program to Transform Autologous Cell Therapy Manufacturing
核心洞察
Adva Biotechnology (搜索) and Autolomous (搜索) have announced a strategic collaboration to co-lead the Digital Pioneer Program, an early adopter initiative focused on digitizing and scaling autologous cell therapy (搜索) manufacturing.
The program integrates Adva's automated closed-system manufacturing platform with Autolomous (搜索)' digital orchestration technologies to create right-first-time production processes with full data traceability and compliance.
The initiative aims to reduce overall time-to-patient for life-saving therapies by enabling automation, digital traceability, and scalability from day one of the therapeutic lifecycle.
Adva Biotechnology (搜索) Ltd. and Autolomous (搜索) Ltd. have announced a strategic collaboration to co-lead the Digital Pioneer Program, an early adopter initiative focused on digitizing, decentralizing, and scaling out autologous cell therapy (搜索) manufacturing. The program represents a significant step toward addressing manufacturing challenges that have historically limited patient access to personalized cell therapies.
Integrated Manufacturing Solution
The collaboration brings together Adva's automated and closed-system manufacturing platform with Autolomous (搜索)' advanced digital orchestration and manufacturing management technologies. This integrated solution is designed to assure right-first-time production processes are developed, with full data traceability and compliance, in order to reduce overall time-to-patient of life-saving therapies.
"Through the Digital Pioneer Program, we are inviting cell therapy developers to experience the real-world benefits of a unified, intelligent manufacturing model," said Dr. Ohad Karnieli, Founder and CEO of Adva Biotechnology (搜索). "This collaboration is about enabling a new standard—one where automation, digital traceability, and scalability are built into the therapeutic lifecycle from day one."
Technology Platform Integration
Adva Biotechnology (搜索)'s flagship product, the ADVA X3 platform (搜索), serves as a fully controlled, smart, flexible, and automated cell processing system. The platform leverages the unique CAMP (Continuous Adaptive Multi-Parameter) technology, which streamlines autologous cell therapy (搜索) manufacturing processes through automation, metabolic sensing, and artificial intelligence.
Autolomous (搜索) contributes its autoloMATE (搜索) software platform, which offers a comprehensive suite of features for electronic batch records, data management, orchestration, and quality release, ensuring cGMP compliance and facilitating efficient production of life-saving therapies.
Mission and Vision
Alexander Seyf, Co-Founder and CEO of Autolomous (搜索), emphasized the program's broader objectives: "Our mission is simple: to bring life-saving therapies to all patients around the world, safer, faster, and affordable. By providing a digital-first infrastructure to the industry, we are removing the barriers between innovation and the patient. This program is a call to action, offering a foundation that will help us build the future of personalized medicine - one defined by trust, equity, and most importantly, acting for hope."
Program Availability
By joining the Digital Pioneer Program, visionary forerunners will be able to evaluate, pilot, and clinically translate this next-generation manufacturing model. The program is now open for inquiries from cell therapy developers interested in adopting next-generation manufacturing technologies, with Adva and Autolomous (搜索) welcoming committed innovators from across the globe to join their mission.